JP2009535410A - ピロロキノリンキノンおよびその使用 - Google Patents

ピロロキノリンキノンおよびその使用 Download PDF

Info

Publication number
JP2009535410A
JP2009535410A JP2009509708A JP2009509708A JP2009535410A JP 2009535410 A JP2009535410 A JP 2009535410A JP 2009509708 A JP2009509708 A JP 2009509708A JP 2009509708 A JP2009509708 A JP 2009509708A JP 2009535410 A JP2009535410 A JP 2009535410A
Authority
JP
Japan
Prior art keywords
pqq
ischemia
reperfusion
subject
pyrroloquinoline quinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009509708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535410A5 (pt
Inventor
ジョエル エス． カーリナー，
シャカー エー． ムーサ，
ジョージ エル． ドルサノ，
ポール ジェイ． デービス，
Original Assignee
シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド filed Critical シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド
Publication of JP2009535410A publication Critical patent/JP2009535410A/ja
Publication of JP2009535410A5 publication Critical patent/JP2009535410A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009509708A 2006-05-02 2007-05-02 ピロロキノリンキノンおよびその使用 Withdrawn JP2009535410A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79716906P 2006-05-02 2006-05-02
PCT/US2007/010721 WO2007130509A2 (en) 2006-05-02 2007-05-02 Pyrroloquinoline quinones and use thereof

Publications (2)

Publication Number Publication Date
JP2009535410A true JP2009535410A (ja) 2009-10-01
JP2009535410A5 JP2009535410A5 (pt) 2011-06-30

Family

ID=38562815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509708A Withdrawn JP2009535410A (ja) 2006-05-02 2007-05-02 ピロロキノリンキノンおよびその使用

Country Status (3)

Country Link
EP (1) EP2068879A2 (pt)
JP (1) JP2009535410A (pt)
WO (1) WO2007130509A2 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015530374A (ja) * 2012-08-13 2015-10-15 ユニバーシティ・オブ・シンシナティ 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
JP2016512564A (ja) * 2013-03-13 2016-04-28 ユニバーシティ・オブ・シンシナティ Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP2019194173A (ja) * 2018-04-27 2019-11-07 国立大学法人 新潟大学 腎障害の抑制におけるシラスタチンの利用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2067781T3 (pl) * 2006-09-19 2013-12-31 Mitsubishi Gas Chemical Co Pirolochinolinochinon do poprawy stanu w przypadku insulinooporności
WO2010004060A1 (es) 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos
KR101913326B1 (ko) * 2016-03-29 2018-10-30 순천향대학교 산학협력단 실라스타틴을 포함하는, 신장 허혈 재관류 손상의 예방 또는 치료용 약학적 조성물
CN110870866A (zh) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
EP1750805A2 (en) * 2004-05-05 2007-02-14 CLF Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone drugs for treatment of cardiac injury
US20060199241A1 (en) * 2005-03-02 2006-09-07 Hyoungsik Yim Electrochemically and optically monitoring cleaving enzyme activity

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
JP2015530374A (ja) * 2012-08-13 2015-10-15 ユニバーシティ・オブ・シンシナティ 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
JP2018131463A (ja) * 2012-08-13 2018-08-23 ユニバーシティ・オブ・シンシナティ 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
JP2020111617A (ja) * 2012-08-13 2020-07-27 ユニバーシティ・オブ・シンシナティ 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
JP2016512564A (ja) * 2013-03-13 2016-04-28 ユニバーシティ・オブ・シンシナティ Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
US10583103B2 (en) 2013-03-13 2020-03-10 University Of Cincinnati Method of treating heart failure with preserved ejection fraction with probenecid
JP2019194173A (ja) * 2018-04-27 2019-11-07 国立大学法人 新潟大学 腎障害の抑制におけるシラスタチンの利用
US11304919B2 (en) 2018-04-27 2022-04-19 Niigata University Utilization of cilastatin in inhibiting renal disorder

Also Published As

Publication number Publication date
WO2007130509A2 (en) 2007-11-15
WO2007130509A3 (en) 2008-01-10
WO2007130509A9 (en) 2008-02-21
EP2068879A2 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
US20100160367A1 (en) Pharmaceutical compositions containing pyrroloquinoline quinone and nephroprotectant for treating ischemia reperfusion injuries
US20080221145A1 (en) Pyrroloquinoline quinone drugs for treatement of cardiac injury and methods of use thereof
JP2888453B2 (ja) ニューモシスティス−カリニ肺炎の治療用または予防用の製薬組成物
EP0590072B1 (en) Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
KR102372194B1 (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
US6403627B1 (en) Spin trapping pharmaceutical compositions and methods for use thereof
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
JPH10513455A (ja) 緑内障治療用のデプレニル化合物
KR20070116632A (ko) 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
JP2009137971A (ja) 薬剤および薬剤キット
US20120289542A1 (en) Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
JP5693970B2 (ja) ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤
JP2000506170A (ja) 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物
JP2007536256A (ja) 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
CN118632699A (zh) 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病
JP2000507205A (ja) 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
US20050267143A1 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
KR100195651B1 (ko) 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질
TW201500042A (zh) 與血液透析有關的低血壓的治療
JP2000510114A (ja) 抗酸化剤化合物
KR20150058159A (ko) 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료
WO2017022787A1 (ja) 収縮力低下随伴性排尿筋過活動改善剤
WO2010056710A1 (en) Compositions and methods for treating eye diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100420

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110830

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110906